SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases ...
ETF Daily News22h
Massachusetts Financial Services Co. MA Acquires 108,109 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)
Massachusetts Financial Services Co. MA lifted its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 20.2% during the 3rd quarter, Holdings Channel reports. The firm ...
Vertex leads J.P. Morgan's top biotech picks list for 2025
J.P. Morgan said its top biotech picks for 2025 were Vertex, Travere, SpringWorks, PTC Therapeutics, Wave Life Sciences, ...
Seeking Alpha1d
Finding Winners In Biotech, Probably The Riskiest Sector
Key stocks to watch include Tarsus Pharmaceuticals and SpringWorks Therapeutics, both showing strong potential based on ...
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Mutual of America Capital Management LLC
Mutual of America Capital Management LLC trimmed its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free ...
SpringWorks Therapeutics Inc. (SWTX): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from ...
12 NASDAQ Stocks with Biggest Upside Potential According to Analysts
In this article, we’re going to talk about the 12 NASDAQ stocks with biggest upside potential according to analysts. Potomac ...
Fintel on MSN5d
Evercore ISI Group Initiates Coverage of SpringWorks Therapeutics (SWTX) with Outperform Recommendation
Fintel reports that on November 20, 2024, Evercore ISI Group initiated coverage of SpringWorks Therapeutics (NasdaqGS:SWTX) ...
Springworks Therapeutics (SWTX) Gets a Buy from Evercore ISI
Springworks Therapeutics (SWTX – Research Report) received a Buy rating and a $60.00 price target from Evercore ISI analyst Cory Kasimov today.
SpringWorks Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Cory Kasimov initiated coverage of SpringWorks Therapeutics (SWTX) with an Outperform rating and $60 price target ...